Loading…
Based on limited metadata, the FDA issued a warning letter to Shanghai Institute of Pharmaceutical Industry on August 29, 2019, regarding drug products. Without access to the full letter text or specific subject line, the precise nature of the violations cannot be determined from the available information. The warning pertains to pharmaceutical drug manufacturing or distribution, though the specific issuing office and exact violation count are not documented in this metadata record. To understand the detailed compliance issues and required corrective actions, the complete warning letter would need to be reviewed.